vs
Side-by-side financial comparison of Celcuity Inc. (CELC) and CASTLE BIOSCIENCES INC (CSTL). Click either name above to swap in a different company.
Celcuity Inc. is a clinical-stage biotechnology company specializing in oncology. It develops personalized cancer treatment solutions through its proprietary functional cell analysis technology, targeting unmet medical needs for patients with hard-to-treat solid tumors, with primary operations in the U.S. and partnerships across global biopharmaceutical networks.
Castle Biosciences Inc. is a commercial-stage diagnostic firm that develops and markets proprietary, clinically actionable tests for dermatological conditions such as melanoma and other skin cancers, plus rare diseases. It operates mainly in the U.S. healthcare market, focusing on segments with high unmet need for more accurate diagnostics to guide treatment choices.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $87.0M | ||
| Q3 25 | — | $83.0M | ||
| Q2 25 | — | $86.2M | ||
| Q1 25 | — | $88.0M | ||
| Q4 24 | — | $86.3M | ||
| Q3 24 | — | $85.8M | ||
| Q2 24 | — | $87.0M | ||
| Q1 24 | — | $73.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-501.0K | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-25.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $2.3M | ||
| Q2 24 | — | $8.9M | ||
| Q1 24 | — | $-2.5M |
| Q4 25 | — | 79.0% | ||
| Q3 25 | — | 77.5% | ||
| Q2 25 | — | 79.5% | ||
| Q1 25 | — | 81.4% | ||
| Q4 24 | — | 81.3% | ||
| Q3 24 | — | 81.8% | ||
| Q2 24 | — | 83.3% | ||
| Q1 24 | — | 81.0% |
| Q4 25 | — | -4.4% | ||
| Q3 25 | — | -8.2% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -31.7% | ||
| Q4 24 | — | 4.7% | ||
| Q3 24 | — | 5.9% | ||
| Q2 24 | — | 5.8% | ||
| Q1 24 | — | -7.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.6% | ||
| Q2 25 | — | 5.2% | ||
| Q1 25 | — | -29.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.6% | ||
| Q2 24 | — | 10.3% | ||
| Q1 24 | — | -3.5% |
| Q4 25 | — | $-0.06 | ||
| Q3 25 | — | $-0.02 | ||
| Q2 25 | — | $0.15 | ||
| Q1 25 | — | $-0.90 | ||
| Q4 24 | — | $0.32 | ||
| Q3 24 | — | $0.08 | ||
| Q2 24 | — | $0.31 | ||
| Q1 24 | — | $-0.09 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
